Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluconazole in hypercalciuric patients with elevated 1,25(OH)2D
2020-003011-97Phase 2Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of fluconazole in hypercalciuria, nephrolithiasis and nephrocalcinosis, sponsored by Hospices Civils de Lyon. Primary endpoint: Normalization or reduction of 24-hour calciuria at week 16. Started Sep 2020; status: completed.
02
Drugs
fluconazole
03
Conditions
hypercalciurianephrolithiasisnephrocalcinosis
Beyond the preview
Go deeper on 2020-003011-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003011-97.